- Home
- ACIU vs OPP Comparison
ACIU vs OPP Comparison
Compare ACIU & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- OPP
- Stock Information
- Founded
- ACIU 2003
- OPP 2010
- Country
- ACIU Switzerland
- OPP United States
- Employees
- ACIU N/A
- OPP N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- OPP Finance/Investors Services
- Sector
- ACIU Health Care
- OPP Finance
- Exchange
- ACIU Nasdaq
- OPP Nasdaq
- Market Cap
- ACIU 213.3M
- OPP 204.0M
- IPO Year
- ACIU 2016
- OPP N/A
- Fundamental
- Price
- ACIU $3.36
- OPP $8.05
- Analyst Decision
- ACIU Strong Buy
- OPP
- Analyst Count
- ACIU 2
- OPP 0
- Target Price
- ACIU $10.00
- OPP N/A
- AVG Volume (30 Days)
- ACIU 417.2K
- OPP 108.0K
- Earning Date
- ACIU 11-04-2025
- OPP 01-01-0001
- Dividend Yield
- ACIU N/A
- OPP 14.41%
- EPS Growth
- ACIU N/A
- OPP N/A
- EPS
- ACIU N/A
- OPP N/A
- Revenue
- ACIU $5,482,957.00
- OPP N/A
- Revenue This Year
- ACIU N/A
- OPP N/A
- Revenue Next Year
- ACIU $1,022.98
- OPP N/A
- P/E Ratio
- ACIU N/A
- OPP N/A
- Revenue Growth
- ACIU N/A
- OPP N/A
- 52 Week Low
- ACIU $1.43
- OPP $7.26
- 52 Week High
- ACIU $4.00
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- ACIU 53.82
- OPP 34.79
- Support Level
- ACIU $3.20
- OPP $7.99
- Resistance Level
- ACIU $3.70
- OPP $8.19
- Average True Range (ATR)
- ACIU 0.40
- OPP 0.09
- MACD
- ACIU -0.01
- OPP -0.00
- Stochastic Oscillator
- ACIU 53.28
- OPP 14.63
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.